| Ref ID | 893 |
| First Author | T. Muka |
| Journal | ELIFE |
| Year Of Publishing | 2023 |
| URL | https://elifesciences.org/articles/85679 |
| Keywords |
• COVID • Risk of bias • Oncology • Transparency • Protocols • Low methodological quality • Non-Cochrane reviews • Disclosure |
| Problem(s) |
• Reasons for excluding potentially eligible studies not provided • Conflicts of interest or funding of included studies not assessed • Risk of bias not incorporated into conclusions of review • Low methodological (AMSTAR) quality • No registered or published protocol |
| Article Type | Empirical |
| Article Subtype | Cross-sectional survey/Methodological systematic review |
| First Author Country | Switzerland |
| Checklists |
• AMSTAR 2 |
| Aim | To summarize the findings from systematic reviews on impact of the COVID-19 pandemic on cancer treatment modification, delays, and cancellations; delays or cancellations in screening and diagnosis; psychosocial well-being, financial distress, and use of telemedicine as well as on other aspects of cancer care. |
| Level of Investigation | Descriptive |
| Summary of Findings | From 52 included systematic reviews on impact of the COVID-19 pandemic on cancer treatment modification, delays, and cancellations indexed across PubMed and WHO COVID-19 up to November 2022. Only two reviews scored moderate to high methodological quality using AMSTAR-2, while the rest (43/52; 82.6%) were evaluated as low or critically low quality. Almost half of the included reviews (25/50; 48.0%) did not report a protocol; only 3 provided a list of excluded studies (5.7%) and just 4 reported on sources of funding of included studies (7.6%); an assessment of risk in individual studies when interpreting/discussing the results was only carried out in 8 reviews (15.3%). |
| Number of systematic reviews included | 52 |
| Number of eligible systematic reviews assessed | 1170 |